iVeena Doses First Participant in Phase 1 Trial of IVMED-85 for Myopia Progression

iVeena Delivery Systems announced that the first patient has been dosed in its phase 1, first-in-human clinical study of IVMED-85 in healthy adult volunteers.

The phase 1 trial is designed to evaluate the safety and tolerability of IVMED-85 administered twice daily. The randomized, controlled study is currently enrolling healthy adult volunteers. Dosing is expected to be completed in the second quarter of 2026, with a full data readout anticipated in mid-third quarter 2026.

IVMED-85 is iVeena’s lead investigational therapy and is being developed for the prevention of myopic progression. Data generated from the study will help inform the design of subsequent clinical trials in pediatric patients with progressive myopia. The company plans to initiate a phase 2 study in the second half of 2026.

IVMED-85 is a new chemical entity (NCE) formulated as a preservative-free prescription eye drop for the prevention of myopic progression. The therapy is designed to be non-surgical, noninvasive, and non-atropine-based. It works by strengthening scleral and corneal collagen crosslinks through activation of lysyl oxidase (LOX), a mechanism that may improve refraction and reduce the rate of axial elongation associated with myopia.

Originally published online on Eyewire+.